Description
Background:
Ubamatamab is a human bispecific antibody designed to bridge MUC16 on cancer cells with CD3-expressing T cells to facilitate T-cell activation and cytotoxicity. It is designed to trigger rapid internalization of this complex into cancer cells to degrade the MET receptor and block its ability to support cell proliferation. Preclinical models examining immune-deficient mice have shown that ubamatamab combined with human immune cells led to dose-dependent antitumor activity against intraperitoneal MUC16-expressing ovarian tumor cells and malignant ascites. Preclinical trials are currently ongoing.
Intended Use:
For Estimation of Ubamatamab in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!